A phase 3 clinical trial of upadacitinib for alopecia areata has shown that more than half of participants on the higher dose restored at least 80% of their scalp and eyebrow hair coverage, with the European Commission subsequently approving the drug for the condition in July 2026, according to the National Alopecia Areata Foundation.
Alopecia areata affects around 2% of the global population. It is an autoimmune disorder in which the immune system attacks hair follicles, triggering hair loss that can be reversed but is difficult to prevent from recurring. The condition carries a well-documented psychosocial burden, including effects on mood and confidence, making effective, durable treatments a genuine clinical priority.
What the Upadacitinib Alopecia Areata Trial Found
The parallel phase 3 trials, which ran from October 2023 to July 2025 according to PubMed, enrolled 1,399 participants aged between 12 and 64, including 118 adolescents. All participants had lost at least 50% of their scalp hair at the point of enrolment. They were randomised to receive either 15 milligrams of upadacitinib, 30 milligrams, or a placebo, over 24 weeks.
Results began to differentiate from placebo as early as week 8. By the end of the trial, 44% of participants on the 15mg dose and 55% on the 30mg dose had achieved 80% or greater scalp and eyebrow hair coverage. Between 13% and 22.5% of participants on upadacitinib, depending on dosage, regained all of their scalp hair.
The headline figures become more striking when a stricter threshold is applied. According to the Dermatology Education Foundation, 36% of patients on 15mg and 47.1% on 30mg reached 90% or more scalp hair coverage, measured by a standard hair loss scoring system, compared with just 1.4% of those receiving placebo at week 24. The dose-response pattern across both thresholds points consistently toward greater efficacy at the higher level.
Quality-of-life measurements also improved for many participants by the study’s end, including outcomes related to depression, an acknowledgement by the authors that hair regrowth carries weight beyond the cosmetic. As the trial’s authors wrote: ‘In a disease often associated with sizable psychosocial and emotional burden, translation of clinical responses (hair regrowth) into meaningful patient-reported improvements becomes imperative to deem a treatment to be efficacious.’
Safety Profile and the Conflict-of-Interest Caveat
The safety data were broadly reassuring but not without caveats. A small number of participants experienced serious side effects. One patient developed breast cancer; that individual had returned concerning mammogram results before the trial began. Two further serious side effects were reported that could reasonably be believed to have been caused or aggravated by the drug, both in participants who could be described as being at very high risk for health complications. No deaths were reported, and none of the side effects that emerged were novel to the drug class.
The trial was industry-funded and included employees of the company that produces upadacitinib. The study passed independent peer review, but those financial ties are a legitimate reason to treat the results as a strong signal rather than a settled answer. Further research conducted without those conflicts of interest would substantially strengthen the evidence base before the drug becomes a standard-of-care option for alopecia.
Where Upadacitinib Sits in the Treatment Landscape
The broader regulatory picture gives the trial results additional context. Three oral JAK inhibitors are already approved by the US Food and Drug Administration for severe alopecia areata: baricitinib (Olumiant), approved in June 2022; ritlecitinib (Litfulo), approved in June 2023; and deuroxolitinib (Leqselvi), approved in July 2024, according to Contemporary Pediatrics. Upadacitinib was selected for this trial partly because of mechanistic similarities with those existing medications.
The European Commission’s July 2026 approval, covering adults and adolescents aged 12 and older with severe alopecia areata, means the drug is now authorised for clinical use on one side of the Atlantic. That regulatory step gives patients and clinicians in Europe a concrete new option while FDA review continues, and it sets a defined next milestone for the drug’s global uptake.
